secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001213900-24-060795
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech appoints Dr. Marco Gottardis to Board of Directors
----------------------------------------------------------------

- Dr. Gottardis fills Class I director vacancy created by Alana McNulty's resignation, effective July 11, 2024.
- Appointed to Audit, Compensation, and Nominating committees; annual retainer of $40,000 plus committee retainers.
- Received sign-on option for 300,000 shares at $2.00 per share, vesting monthly over three years.
- Background: former VP of Oncology Innovation at Janssen (JNJ) and Senior VP at Replay Bio Holdings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/ea0209333-8k_nkgen.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-060795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer